Posters, Presentations & Publications Archives - Kymera Therapeutics

Preliminary Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia and Solid Tumors

12/10/23

IRAK4 Degradation vs Inhibition

11/14/23

IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial

11/13/23

Development of KT-253, a highly potent and selective heterobifunctional MDM2 degrader, for the treatment of Acute Myeloid Leukemia

10/16/23

The MDM2 degrader KTX-049 is highly potent in TP53 wild-type (p53 WT) Merkel cell carcinoma (MCC)

10/16/23

Discovery of KT-474, a potent, selective, and orally bioavailable IRAK4 degrader for the treatment of autoimmune diseases

9/26/23

Targeted degradation of MERTK and other TAM receptor paralogs by heterobifunctional targeted protein degraders

7/24/23

Phase 1 trial of KT-333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors

6/14/23

Pulse Dosing of Potent and Selective Heterobifunctional MDM2 Degrader KT-253 Drives Tumor Regression and Demonstrates Differentiated Pharmacology Compared to p53/MDM2 Small Molecule Inhibitors

6/9/23

Safety and Efficacy of IRAK4 Degrater KT-474 (SAR444656) for Hidradenitis Suppurativa and Atopic Dermatitis

5/18/23

×